These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 14871851)
1. Potent antitumor activity of interleukin-27. Hisada M; Kamiya S; Fujita K; Belladonna ML; Aoki T; Koyanagi Y; Mizuguchi J; Yoshimoto T Cancer Res; 2004 Feb; 64(3):1152-6. PubMed ID: 14871851 [TBL] [Abstract][Full Text] [Related]
2. Augmentation of effector CD8+ T cell generation with enhanced granzyme B expression by IL-27. Morishima N; Owaki T; Asakawa M; Kamiya S; Mizuguchi J; Yoshimoto T J Immunol; 2005 Aug; 175(3):1686-93. PubMed ID: 16034109 [TBL] [Abstract][Full Text] [Related]
3. Synergistic antitumor effect by coexpression of chemokine CCL21/SLC and costimulatory molecule LIGHT. Hisada M; Yoshimoto T; Kamiya S; Magami Y; Miyaji H; Yoneto T; Tamada K; Aoki T; Koyanagi Y; Mizuguchi J Cancer Gene Ther; 2004 Apr; 11(4):280-8. PubMed ID: 15002032 [TBL] [Abstract][Full Text] [Related]
4. Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals. Chiyo M; Shimozato O; Yu L; Kawamura K; Iizasa T; Fujisawa T; Tagawa M Int J Cancer; 2005 Jun; 115(3):437-42. PubMed ID: 15688376 [TBL] [Abstract][Full Text] [Related]
5. Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-gamma: a role for intrinsic tumor immunogenicity and IL-15. Gri G; Chiodoni C; Gallo E; Stoppacciaro A; Liew FY; Colombo MP Cancer Res; 2002 Aug; 62(15):4390-7. PubMed ID: 12154045 [TBL] [Abstract][Full Text] [Related]
6. Spleen-derived dendritic cells engineered to enhance interleukin-12 production elicit therapeutic antitumor immune responses. Furumoto K; Arii S; Yamasaki S; Mizumoto M; Mori A; Inoue N; Isobe N; Imamura M Int J Cancer; 2000 Sep; 87(5):665-72. PubMed ID: 10925360 [TBL] [Abstract][Full Text] [Related]
7. Lineage-specific requirement for signal transducer and activator of transcription (Stat)4 in interferon gamma production from CD4(+) versus CD8(+) T cells. Carter LL; Murphy KM J Exp Med; 1999 Apr; 189(8):1355-60. PubMed ID: 10209051 [TBL] [Abstract][Full Text] [Related]
9. Induction of systemic immunity by expression of interleukin-23 in murine colon carcinoma cells. Wang YQ; Ugai S; Shimozato O; Yu L; Kawamura K; Yamamoto H; Yamaguchi T; Saisho H; Tagawa M Int J Cancer; 2003 Jul; 105(6):820-4. PubMed ID: 12767068 [TBL] [Abstract][Full Text] [Related]
10. IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice. Di Carlo E; Comes A; Orengo AM; Rosso O; Meazza R; Musiani P; Colombo MP; Ferrini S J Immunol; 2004 Feb; 172(3):1540-7. PubMed ID: 14734732 [TBL] [Abstract][Full Text] [Related]
11. T-bet is a STAT1-induced regulator of IL-12R expression in naïve CD4+ T cells. Afkarian M; Sedy JR; Yang J; Jacobson NG; Cereb N; Yang SY; Murphy TL; Murphy KM Nat Immunol; 2002 Jun; 3(6):549-57. PubMed ID: 12006974 [TBL] [Abstract][Full Text] [Related]
12. Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. Narvaiza I; Mazzolini G; Barajas M; Duarte M; Zaratiegui M; Qian C; Melero I; Prieto J J Immunol; 2000 Mar; 164(6):3112-22. PubMed ID: 10706701 [TBL] [Abstract][Full Text] [Related]
13. In vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunity. Sun Y; Peng D; Lecanda J; Schmitz V; Barajas M; Qian C; Prieto J Gene Ther; 2000 Sep; 7(17):1467-76. PubMed ID: 11001366 [TBL] [Abstract][Full Text] [Related]
14. Lack of interleukin-6 in the tumor microenvironment augments type-1 immunity and increases the efficacy of cancer immunotherapy. Ohno Y; Toyoshima Y; Yurino H; Monma N; Xiang H; Sumida K; Kaneumi S; Terada S; Hashimoto S; Ikeo K; Homma S; Kawamura H; Takahashi N; Taketomi A; Kitamura H Cancer Sci; 2017 Oct; 108(10):1959-1966. PubMed ID: 28746799 [TBL] [Abstract][Full Text] [Related]
15. Expression of the interleukin-21 gene in murine colon carcinoma cells generates systemic immunity in the inoculated hosts. Ugai S; Shimozato O; Kawamura K; Wang YQ; Yamaguchi T; Saisho H; Sakiyama S; Tagawa M Cancer Gene Ther; 2003 Mar; 10(3):187-92. PubMed ID: 12637939 [TBL] [Abstract][Full Text] [Related]
16. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Martinotti A; Stoppacciaro A; Vagliani M; Melani C; Spreafico F; Wysocka M; Parmiani G; Trinchieri G; Colombo MP Eur J Immunol; 1995 Jan; 25(1):137-46. PubMed ID: 7843224 [TBL] [Abstract][Full Text] [Related]
17. TGF-beta 1 uses distinct mechanisms to inhibit IFN-gamma expression in CD4+ T cells at priming and at recall: differential involvement of Stat4 and T-bet. Lin JT; Martin SL; Xia L; Gorham JD J Immunol; 2005 May; 174(10):5950-8. PubMed ID: 15879087 [TBL] [Abstract][Full Text] [Related]
18. Regression of engineered myeloma cells secreting interferon-gamma-inducing factor is mediated by both CD4(+)/CD8(+) T and natural killer cells. Xiang J; Chen Z; Huang H; Moyana T Leuk Res; 2001 Oct; 25(10):909-15. PubMed ID: 11532525 [TBL] [Abstract][Full Text] [Related]